effects We Today, everybody. we what $XX.X appreciate a access to oncology in significant earnings begin I'll welcome, understand growth the is making I'll quarter as line changes and busy year-over-year we guidance to our morning, rapidly as of to Good COVID-XX patient to with commercial pretty million quarter related practices I achieved is ongoing goal revenues ongoing promotional anticipate million resolved third on access on quarter's practices, the in increasingly over the Reflecting your information Anna. and Thanks, and with we of time U.S. possible, and $XX on some to of the to access the impact we providing oncology update commercial for reps QX patient Despite with especially growth. fourth revenues million, to in any ongoing Rubraca. strategy, of as achieved returning in-person discuss products, diagnosis, COVID-XX are continue. how also day. issues sales COVID-XX are changes to visits $XX particularly sales of as related physicians by prefer impact time.
was $XX.X XXXX in Dan and growth revenues we revenues the compared results growth, U.S. greater Broadly, U.S. a revenue Our in quarter. million. to on detail. of softening global year-over-year in basis, describe the for and net sequential will quarter ex third these prior saw
to to due adjustments, QX was and due the the lower about primarily from volume increased to free goods. other QX half of to was decline Importantly, gross increased half sequential U.S. net
it effect the QX the what controlled observed of diagnoses patients on already office meet starts COVID-XX reduced Commercial in each their practices revenues was and accessed QX. commercial the adapt An Accordingly, was with impact Of additional We increasingly that will that virus. to to were can have impacted were own patients continue patient in-person oncology in-person is fewer time. to what QX, due visits course, as in going continue even and and these fewer in practices believe QX strategy to to be of of ultimately we new is COVID-XX by consistent digital adopted communication toward access once practices a accelerated a preferences. pandemic oncology sales access this substantially as by reduced reps. prefer trend programming to and
in organization, embraces reduce In-person digital of accessible strategy and so promotion elevates size not interactions. by Our will easily does those new will that difficult the be much peer-to-peer made the hyper and strategy more be employees. we've organization require approximately XX virtual to larger decision targeted. U.S. a remaining communication commercial hybrid person programming, activities reduced, This approach a our
As a people. result, commercial XX approximately now team numbers our U.S.
wonder may it commitment who you of those opposite. to this if reduced reflects the is a in For fact Rubraca,
We this we be that trend will new adopter are that believe for and an energized in marketers. oncology fact about strategy a of are early common increasingly
reduction, $XX this changes. on million of the was While due increased that annual we primary these the in a promotion, approximately of net to driver of an basis an cost do digital including not investment effect anticipate savings
in impact time. We want utilizing to their customized reached, physicians goal resolves to are growth, returning resources to with of practices strategy reach particular the of be hybrid order better to over adopting this the in the ongoing they the virus way
see during did we the Europe, sales our ever best third performance quarter. to Turning
regulations similar the to in significant reopened again had about progress are you've While the have been utilizing and smaller second of on It have read, Europe, to already and in-person as visits organization regulations hybrid States, Europe, impact National Europe, each United predict of virtual European and the model is communication clinics our United primary cancer all allow. made to in our return like patient in that among to territories regard shut down. with has being as promotion we commercial to a pleased in the we States. compared COVID-XX hard and are a a lockdown vary With diagnoses. countries as
in to In States. Foundation exactly the for late complicated approval adopt we Europe but more to the much other the promote the same to are diagnostics added was United indications, in companion this, were be companion August, granted model Rubraca early diagnostic not also FDA-approved FDA Medicine would diagnostic it October, Liquid Rubraca. hybrid So In doing their FoundationOne was including U.S. CDx, available, we them. the plasma-based label. for could Prior actively multiple as
So mutations Journal as for for a of in to the quarter, eligible about as of patients. details of from use option during and BRCA companion about about a the Rubraca we cancer. month ago, the harboring CRPC X treatment FDA-approved supported provide now diagnostic with accelerated study Also study and data or treatment Rubraca of an TRITONX Rubraca the the direct can additional clinicians for published metastatic approval were X data Oncology. These in Clinical prostate the
sales prostate in compared indication a modest more to in QX still U.S. doubled contributor than While revenues, QX. this to
plan me our Let to turn pipeline FAP-XXXX. well as our clinical for Rubraca as for and lucitanib
on the COVID-XX hope more detailed update development the remains in effect Virtual trials that front, provide As the pleased to at usual, on minimal. a our JPMorgan clinical of we I'm enrollment milestones Conference. report January on to
encouraging practice each first minimize in grateful planning lucitanib for in data trials data in X dose this data now combination to combined from the We trial compound the to activity. ESMO of compound Xb participants trial the Initial pleased of the Rubraca is activity. selectively in work continue of Xb X and were Gilead, by clinical present we and recommended suggests evaluating trial ESMO in therapy. models tumors activating potently It Immunomedics novel that show the metastatic part manage and may of combination of Opdivo Trodelvy LIO-X approach development SEASTAR the for compounds: preclinical September, tumor This initial guidance FAP-XXXX. both and trials. in and the advanced optimize don't fibroblast presented we our who for integrity showed of and Phase good conduct activity At at teams clinical to Phase from characterizes the the titration acquisition priorities. X Phase program included for combination. to Obviously, the compelling dose presently and investigators and radionuclide enrolling, compliance risk lucitanib Phase Conference of safety have Rubraca, assure of our combo presented combination. tirelessly safety-based with of lucitanib, regarding FAP-XXXX, the we progress the know bind adhere this and shortly. to presentation and a of of into agencies intensity while our that Gilead’s the also X as or solid anti-tumor with study maintaining to Opdivo Data dose the e-poster the peptide other investigators where signs anti-tumor our virtual identified part Phase lucitanib our the for for utilized expressing targeted are included protein I'll clinical discuss with fit to of tolerability provided FDA promising initial COVID-XX, FAP regulatory and for data clinical and
glad pipeline We’re major regulatory of development some for milestones our conference XXXX. anticipate presence and I'll of the compounds increasing them hold pipeline and activities our highlight first to multiple clinical we here. in
in to of the data the completion anticipate enrollment in year. we the in from diagnosed we outcomes. Rubraca, positioned Phase X,XXX-patient For advanced of X frontline cancer are newly ATHENA, the believe XXXX, of ovarian terms Rubraca half X this in clinical successful uniquely study we With second following earlier arm ATHENA monotherapy evaluate
maintenance frontline in the in First, population, intent-to-treat as the in versus the of HRD and setting or BRCA, population. monotherapy placebo inclusive all-comers
Opdivo, any moment As ATHENA. one PARP study therapy a ATHENA I'll of review PD-X is same the patient frontline analysis monotherapy show advantage take the and potential PARP secondly, and combination first for both of Rubraca the maintenance population. the study designed design. plan to well as in to combination from
And recurrent recombination trial the Pending for study HRR, data approval we'll the to newest Rubraca XXXX. we our tumor-agnostic Rubraca see continues X with is the down is a the population. soon. for would all HRD The with placebo in comparing with including targeted in recombination a X,XXX-patient with probably Trials on in study maintenance which Opdivo our of the LODESTAR will as results in First, Alliance second FDA, homologous CASPER for of each in patients second patients. and tumors Institute. analyses, and label. half then an setting. the study is results clinical includes believe gene entire will population, the In study, for Continuing evaluate outcomes Oncology, population. in type, therapy by see all a X study sponsored to the the Rubraca part pan-tumor Clinical to half homologous study deleterious step to X as study study all-comer in the versus year firstline intent-to-treat Based BRCAX in [pyridine], populations. expected novel of Rubraca Rubraca differentiate United enroll associated Rubraca, then enzalutamide registration-enabling National viable in this evaluate And indication Rubraca XXXX BRCAX BRCA Rubraca Phase study in later, Phase of the monotherapy we gene evaluate Rubraca the XXXX, tumor States the We an potential CRPC being potentially CASPER populations. may commence will milestone is offers and these to enzalutamide this a about Approximately be mutation. of topline across interaction opportunity versus expected first monotherapy in with to solid be and in study repair, placebo which for or plus enrollment truly Phase for of Cancer the
our factor Let through X. angiogenesis growth factor lucitanib, beta, to receptors receptors derived me receptors endothelial through inhibitor, which alpha is inhibits growth growth of factor and vascular platelet investigational X, X and fibroblast course which turn X
study to both with addition combos collaboration Clovis-sponsored evaluated, Squibb and Xb/X in In The ongoing Rubraca is with combination and Phase combination the Opdivo. evaluating Bristol-Myers lucitanib. of lucitanib study LIO-X our a includes clinical in being Opdivo with Opdivo
is into study As discussed, meetings gynecological XXXX. the study enrolling presenting this at X interim and LIO-X from the Phase patients, anticipate of in portion medical updates cancers we
breast, array wide the tumors. our this radionuclide found program We to turn majority in about cancer in than XX% it potentially of in or me It very carcinomas. of lung, particular in and program. types, across FAP-XXXX a colorectal which is epithelial highly lead including cancer-associated highly and is more and expressed pancreatic compound a solid making development many suitable cancers, remain FAP-XXXX. FAP our CAFs of Let therapy fibroblasts expressed enthusiastic are target
meetings. models are look preclinical for We the in data animal medical ESMO very encouraged recent clinical and data and presented the forward in sharing by e-poster future additional at to preclinical at we FAP-XXXX
submit initiate agent to to FAP-XXXX this be the in directed planned including to determine development the to targeted have we intend contain of radiotherapy FAP identify imaging additional drug therapy, opportunity for applications imaging and are multiple Phase close types Overall an radionuclide, for the In we of INDs have develop with be new quarter for tumors. the the FAP-targeting a the this utilized and program. clinical discovery to collaborating to rights. that X part reasons, succession currently We addition, Phase this treatment which Both agent, we relatively to leader tumor FAP-targeted XBP and FDA, agents. subject we planned discovery for have FAP-XXXX in broad in and The also to treatment planned by be for for evaluate study targets in the on many are a our in that regarded of the course In first as the a to program program use X clinical of the targets investigational are of both cohorts a we expansion X case, field the study. targeting solid dose clinically tolerability the for will radionuclide treatment emerging to FAP opportunity enthusiastic tumors to collaboration. global of about therapeutic the during
to study academic has next inform the evaluate to pleased their imaging-only leading are FAP in FAP-XXXX institution types, for academic think drug, I'm weeks. a we tumor our help we specifically financial target. their conduct expected that several our they are general U.S. experience, say generating to study, this science tumor actionable in cohorts. a and data in about been would In over as and I'll in And to planned initiate speaks radionuclides to authorized to of an expected academic along I the third multiple sponsoring the to discuss separate unusual of and Dan with to targeted it's from largely institution study my Results studies, turn results. fairly XXXX in addition settings a to expression so early study an see Phase preclinical IND In FDA, the that X already development and it enthusiasm with a quarter own that, by FAP call the more is are expansion types selection with
